Completed OBSERVATIONAL NCT04008810

Serum Neutrophil Gelatinase-associated Lipocalins (NGAL) and Chronic Kidney Disease

Serum Neutrophil Gelatinase-associated Lipocalins (NGAL) Ability to Predict Chronic Kidney Disease and the Number of Readmissions in Patients Admitted in the Emergency Department - a Longitudinal Prospective Study

Sponsor: BioPorto Diagnostics

Conditions AKI Acute Kidney Injury CKD Chronic Kidney Diseases Emergency Department NGAL Neutrophil Gelatinase-associated Lipocalin

Updated 8 times since 2019 Last updated: Feb 23, 2025 Started: Oct 3, 2019 Primary completion: Jan 10, 2023 Completion: Jun 3, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates AKI and Acute Kidney Injury and is currently completed. BioPorto Diagnostics leads this study, which shows 8 recorded versions since 2019 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed
Mar 2025 — Sep 2025 [monthly]

Completed

Status: Active Not Recruiting → Completed
Sep 2024 — Mar 2025 [monthly]

Active Not Recruiting
Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting
Apr 2023 — Jul 2024 [monthly]

Active Not Recruiting

Status: Unknown Status → Active Not Recruiting

▶ Show 3 earlier versions

Oct 2021 — Apr 2023 [monthly]

Unknown Status

Status: Not Yet Recruiting → Unknown Status
Jan 2021 — Oct 2021 [monthly]

Not Yet Recruiting
Aug 2019 — Jan 2021 [monthly]

Not Yet Recruiting

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

BioPorto Diagnostics
Hillerod Hospital, Denmark

Data source: Hillerod Hospital, Denmark

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hillerød, Denmark